May 6, 2025
Adding pembrolizumab to standard-of-care treatment improved event-free survival (EFS) in locally advanced head and neck squamous cell carcinoma (HNSCC), according to new results of the KEYNOTE-689 […]
May 6, 2025
TOPLINE: Among women aged 70 years or older with screen-detected breast cancer, those with a history of screening mammography within 5 years of their diagnosis were […]
May 5, 2025
TOPLINE: In a real-world analysis, the relative risk of myelodysplastic syndrome (MDS) and acute myeloid leukaemia (AML) was higher in patients who received chemotherapy plus poly(ADP-ribose) […]
May 5, 2025
A trial testing the combination of the anti-TIGIT antibody tiragolumab and atezolizumab vs atezolizumab in previously untreated programmed cell death ligand 1 (PD-L1)–high locally advanced unresectable […]
May 5, 2025
TOPLINE: Racial and ethnic disparities in the use of targeted therapy among patients with ERBB2-positive breast cancer decreased among older Medicare beneficiaries between 2010 and 2019. […]
May 5, 2025
Lingering fatigue and depression are more common among women than men cancer survivors and often lead to a decrease in recreational physical activities in all patients, […]
May 2, 2025
TOPLINE: A third of patients with high-risk prostate cancer identified as biomarker-negative by an artificial intelligence (AI)–derived tool were safe to forgo long-term androgen deprivation therapy […]
May 1, 2025
Cervical cancer screening guidelines in the United States have evolved considerably over the past few decades, reflecting advances in understanding how cervical cancer develops, the pivotal […]
May 1, 2025
The European Medicines Agency’s (EMA) committee on human medicines has approved extended indications for two medicines used to treat Hodgkin disease and leukemia, respectively. In Hodgkin […]